Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision genome editing biotech developing base and prime editors for rare genetic diseases; improved specificity over first-generation CRISPR competing with Beam Therapeutics and Intellia.
Veda Bio is a biotechnology company developing novel therapeutics for rare genetic diseases and cancer using its proprietary precision genome editing platform — enabling targeted genetic corrections with greater specificity and reduced off-target editing compared to first-generation CRISPR tools. Founded in 2019 and headquartered in Seattle, Washington, Veda Bio was founded by genome editing pioneers and has raised early-stage funding to develop its differentiated editing technology platform.\n\nVeda Bio's platform focuses on delivering precision genetic medicine that can address root causes of genetic diseases rather than managing symptoms. The company's approach aims to improve on first-generation CRISPR-Cas9 by developing base editors and prime editors that can make specific genetic corrections (single letter DNA changes, small insertions or deletions) without introducing double-strand DNA breaks that create higher off-target editing risk. This precision is critical for therapeutic applications where off-target genomic changes could have serious safety consequences.\n\nIn 2025, Veda Bio operates in the competitive genome editing therapeutics space alongside Intellia Therapeutics, Beam Therapeutics (base editing pioneer), Prime Medicine, and CRISPR Therapeutics. The genome editing field experienced a landmark moment in 2023 with the FDA approval of Casgevy (the first CRISPR-based therapy, for sickle cell disease and beta-thalassemia, developed by Vertex and CRISPR Therapeutics) — validating the genome editing therapeutic modality and creating competitive pressure for improved precision editing platforms. Veda Bio's 2025 strategy focuses on advancing lead programs in rare genetic indications through preclinical development toward IND applications, publishing research to establish scientific credibility, and exploring partnerships or licensing with larger biopharmaceuticals for clinical development.
US YC W20 AI interior design platform with style preference discovery and room visualization; generating personalized moodboards and shoppable décor matches competing with Houzz for AI-native home design discovery.
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal design aesthetic, visualize how spaces would look with different furniture and décor, and find matching products from online retailers. Users select style preferences (mid-century modern, bohemian, minimalist, coastal) and color palettes (navy, salmon, olive, beige) and receive AI-generated moodboards and room transformation visuals in seconds — with the platform linking out to purchasable products that match the visualized design. Founded in 2020 and enhanced with more sophisticated AI algorithms in 2024-2025, Oda Studio serves the design discovery and product-matching need that exists in the early stages of home decorating before interior designers are typically engaged.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.